5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Segment C, individuals will acquire ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will receive treatment until eventually ailment progression or the members are unable to tolerate the study drugs.then promote H3K27Ac at this area. Chromatin hyperacetylation could enhance the accessibility i